Progenics, Salix tumble on US FDA snub for expanded Relistor marketing
This article was originally published in Scrip
Executive Summary
Shares of Tarrytown, New York-based Progenics lost half their value on 30 July on word the US FDA refused to let the company and its partner Salix Pharmaceuticals market Relistor (methylnaltrexone bromide) injection as a subcutaneous treatment for opioid-induced constipation (OIC) in adults with chronic, non-cancer pain.